MaxCyte, Inc. (MXCT) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MXCT Revenue Growth
Revenue Breakdown (FY 2024)
MXCT's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
MXCT Revenue Analysis (2014–2025)
As of May 9, 2026, MaxCyte, Inc. (MXCT) generated trailing twelve-month (TTM) revenue of $33.0 million, reflecting significant decline in growth of -16.0% year-over-year. The most recent quarter (Q4 2025) recorded $7.3 million in revenue, up 6.9% sequentially.
Looking at the longer-term picture, MXCT's 5-year compound annual growth rate (CAGR) stands at +4.8%, indicating moderate growth over time. The company achieved its highest annual revenue of $44.3 million in 2022.
Revenue diversification analysis shows MXCT's business is primarily driven by Product (95%), and Product and Service, Other (5%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including BTBT, LNTH (+0.6% YoY), and NVAX (-52.5% YoY), MXCT has underperformed the peer group in terms of revenue growth. Compare MXCT vs BTBT →
MXCT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MXCTCurrent | $33M | -16.0% | +4.8% | -138.3% | |
 BTBT | $164M | - | - | 16.8% | |
 LNTH | $1.5B | +0.6% | +35.3% | 20.2% | |
 NVAX | $1.1B | -52.5% | +118.8% | 50.1% | |
 BCYC | $73M | +146.9% | +47.5% | -341.3% |
MXCT Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $33.0M | -14.5% | $26.8M | 81.2% | $-45,675,000 | -138.3% |
| 2024 | $38.6M | -6.4% | $31.5M | 81.6% | $-51,197,000 | -132.5% |
| 2023 | $41.3M | -6.7% | $36.5M | 88.5% | $-48,299,000 | -117.0% |
| 2022 | $44.3M | +30.6% | $39.2M | 88.5% | $-27,361,000 | -61.8% |
| 2021 | $33.9M | +29.5% | $30.2M | 89.2% | $-18,188,600 | -53.7% |
| 2020 | $26.2M | +21.0% | $23.4M | 89.4% | $-11,056,700 | -42.3% |
| 2019 | $21.6M | +29.7% | $19.1M | 88.4% | $-12,420,000 | -57.4% |
| 2018 | $16.7M | +19.2% | $14.8M | 89.0% | $-8,424,900 | -50.5% |
| 2017 | $14.0M | +14.0% | $12.5M | 89.6% | $-9,291,700 | -66.4% |
| 2016 | $12.3M | +32.1% | $11.0M | 89.3% | $-2,723,400 | -22.2% |
See MXCT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MXCT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MXCT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMXCT — Frequently Asked Questions
Quick answers to the most common questions about buying MXCT stock.
Is MXCT's revenue growth accelerating or slowing?
MXCT revenue declined -16.0% year-over-year, contrasting with the 5-year CAGR of +4.8%. TTM revenue fell to $33M. This reverses the prior growth trend.
What is MXCT's long-term revenue growth rate?
MaxCyte, Inc.'s 5-year revenue CAGR of +4.8% reflects the variable expansion pattern. Current YoY growth of -16.0% is below this long-term average.
How is MXCT's revenue distributed by segment?
MXCT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.